Linden Thomas Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Linden Thomas Advisory Services's REGN Position: Q3 2026 in Review
Linden Thomas Advisory Services increased its Regeneron Pharmaceuticals (REGN) stake by 0.14% in Q3 2026, buying an estimated $5.29K and bringing the position to 5,113 shares worth $3.88M. The position accounts for 0.31% of the portfolio, ranked #88.
Linden Thomas Advisory Services first reported a position in REGN in Q4 2022 and has held it in 16 quarters since. The position peaked at $3.96M in Q1 2026. 1,409 funds tracked by Wall St. Rank hold REGN as of Q3 2026.
- Linden Thomas Advisory Services held 5,113 shares of Regeneron Pharmaceuticals worth $3.88M as of Q3 2026.
- Linden Thomas Advisory Services bought 7 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $5.29K.
- Regeneron Pharmaceuticals made up 0.31% of Linden Thomas Advisory Services's portfolio in Q3 2026, its #88 holding.
- Linden Thomas Advisory Services first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
- Linden Thomas Advisory Services's Regeneron Pharmaceuticals position peaked at $3.96M in Q1 2026.
- 1,409 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.
Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.